TITLE:
A Study of Neutrexin Plus Leucovorin in the Treatment of Pneumocystis Carinii Pneumonia (PCP)

CONDITION:
Pneumonia, Pneumocystis Carinii

INTERVENTION:
Trimetrexate glucuronate

SUMMARY:

      To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection
      in patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have
      demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or
      parenteral pentamidine).
    

DETAILED DESCRIPTION:

      Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21
      days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate
      glucuronate. Patients are followed for 1 month.
    

ELIGIBILITY:
Gender: All
Age: 2 Years to N/A
Criteria:

        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Myelosuppressive or nephrotoxic agents at the discretion of the treating physician.

        Patients must have:

          -  Pneumocystis carinii pneumonia (PCP) confirmed within 15 days prior to study entry.

          -  Serious intolerance and/or resistance to standard therapies (such as
             trimethoprim/sulfamethoxazole and parenteral pentamidine) during the course of
             therapy for the current episode of PCP, or a documented history of such intolerance
             during a prior episode.

          -  Consent of parent or guardian if less than 18 years of age.

        NOTE:

          -  Pregnant women may enroll after the physician and patient have discussed the
             potential benefit versus risk.

        Exclusion Criteria

        Patients with the following prior conditions are excluded:

        History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),
        exfoliative dermatitis, or other life-threatening reactions due to trimetrexate
        glucuronate.
      
